Human Papillomavirus Recombinant Vaccine nonavalent clinical trials
Its developmentBy 5 companies, company by company25 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses Human Papillomavirus Recombinant Vaccine nonavalent is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Human Papillomavirus Recombinant Vaccine nonavalent studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Dec 2014 · Gardasil 9 · BLA 125508 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
74 studies that test it; most in 2022 (10)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 8 |
| 2021 | 6 |
| 2022 | 10 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 51
Merck Sharp & Dohme LLC (20) · National Cancer Institute (NCI) (5) · Indiana University (2) · Boston Medical Center (2) · London School of Hygiene and Tropical Medicine (2) · Emory University (2) · Fred Hutchinson Cancer Center (2) · Shanghai Bovax Biotechnology Co., Ltd. (2)
Often tested with
Tested in the same studies.
Human papillomavirus vaccine, L1 type 16, 18 (4) · Meningococcal Vaccines (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Lidocaine (1) · 2019-nCoV Vaccine mRNA-1273 (1) · Papillomavirus Vaccines (1) · Imiquimod (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Human Papillomavirus Recombinant Vaccine nonavalent is the comparator. A study of two new drugs counts under both.
- 2Escherichia coli · Beijing Health Guard Biotechnology, Inc
Reaching primary completion within a year · 8, 1 in phase 3
Studies that test Human Papillomavirus Recombinant Vaccine nonavalent, phase 3 first.
- Jan 2027Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)Phase 3 · Merck Sharp & Dohme LLC
- Dec 2026An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination RegimenPhase 4 · Boston Medical Center
- Dec 2026Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.Phase 4 · Massachusetts General Hospital
- Dec 2026A Cervical Cancer Prevention Program in KenyaNot applicable · Indiana University
- Jan 2027Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIVPhase 2 · University of Maryland, Baltimore
- Jan 2027Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO TrialPhase 4 · National Cancer Institute (NCI)
- Feb 2027Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPVPhase 2 · Institut d'Investigació Biomèdica de Bellvitge
- Jun 2027Intralesional Gardasil-9 for the Treatment of Recalcitrant WartsPhase 2 · Rush University Medical Center
Studies
Open first, then newest update. How each study uses Human Papillomavirus Recombinant Vaccine nonavalent is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 74
- ESCUDDO Long Term Follow UpEnrolling by invitationPhase 4National Cancer Institute (NCI)NCT07706673Written as Recombinant Human Papillomavirus Nonavalent Vaccine
- The Mother-Daughter Project: Merck-4RecruitingNot applicableIndiana UniversityNCT07240220Written as Gardasil-9
- Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*Not yet recruitingPhase 1/2Ohio State UniversityNCT07339163Written as GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
- A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07785843Written as V503
- Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSILRecruitingPhase 4Erasmus Medical CenterNCT06052696Written as Gardasil 9 Suspension for Injection
- HPV Vaccine Reduced DoseRecruitingPhase 4Emory UniversityNCT06799494Written as Gardasil-9
- Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIVRecruitingPhase 2University of Maryland, BaltimoreNCT06624839Written as Human papillomavirus (HPV) vaccine, 9-valent
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV VaccinationRecruitingPhase 2Universiteit AntwerpenNCT07407569Written as Gardasil 9 (2 dose regimen)
- Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical LesionsRecruitingPhase 2Centre Oscar LambretNCT06658405Written as Human Papillomavirus 9-valent Vaccine, Recombinant
- Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPVNot yet recruitingPhase 2Institut d'Investigació Biomèdica de BellvitgeNCT07303751Written as Nonavalent HPV vaccine (9vHPV)
- A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIVRecruitingPhase 4University of British ColumbiaNCT05495906Written as Nonavalent HPV vaccine
- Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIVRecruitingPhase 4Louisiana State University Health Sciences Center in New OrleansNCT05266898Written as Human papillomavirus 9-valent vaccine, recombinant
- Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus ExposureNot yet recruitingPhase 2National Institute of Hygiene and Epidemiology, VietnamNCT06681636Written as Human papillomavirus 9-valent vaccine, Recombinant
- Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in RwandaNot yet recruitingPhase 4Rwanda Biomedical CentreNCT06536855Written as Gardasil 9
- Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsRecruitingPhase 3Shanghai Bovax Biotechnology Co., Ltd.NCT04895020Written as 9-valent HPV vaccine
- Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous WartsRecruitingPhase 2/3Western Institute for Veterans ResearchNCT05625633Written as Human Papillomavirus 9-valent Vaccine, Recombinant
- Immunogenicity of 9-valent HPV VaccineRecruitingPhase 4Talia Sainz CostaNCT05439083Written as 9-valent HPV vaccine
- HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSILNot yet recruitingPhase 2University Health Network, TorontoNCT03947775Written as 9-valent HPV vaccination
- Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in SwedenRecruitingPhase 4Miriam ElfströmNCT04910802Written as Gardasil9
- Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9Not yet recruitingPhase 3Alessandro GhelardiNCT03848039Written as Gardasil-9
See all 74 studies that test Human Papillomavirus Recombinant Vaccine nonavalent →
Given beside what is tested · 5 — Human Papillomavirus Recombinant Vaccine nonavalent is usual care or a partner of the new treatment
- Testing RG1-VLP Vaccine to Prevent HPV-related CancersRecruitingPhase 1National Cancer Institute (NCI)NCT05985681Written as Recombinant Human Papillomavirus Nonavalent Vaccine
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy AdolescentsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT04490018Written as Human Papillomavirus 9-valent Vaccine (9vHPV)
- A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownPhase 2Sinocelltech Ltd.NCT05060484Written as Gardasil®9
- A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownPhase 1Sinocelltech Ltd.NCT04921111Written as Gardasil®9
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)CompletedPhase 3Merck Sharp & Dohme LLCNCT00988884Written as V503
As the comparator · 10 — what is tested is compared with Human Papillomavirus Recombinant Vaccine nonavalent
- Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) VaccineNot yet recruitingPhase 1/2Serum Institute of India Pvt. Ltd.NCT07888686Written as Gardasil9
- Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).RecruitingPhase 1Merck Sharp & Dohme LLCNCT06623409Written as GARDASIL®9 (G9)
- A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)Active, not recruitingPhase 1Merck Sharp & Dohme LLCNCT06688058Written as GARDASIL®9
- A Clinical Study of V540A in Healthy Female Participants (V540A-005)WithdrawnPhase 2Merck Sharp & Dohme LLCNCT07224477Written as GARDASIL®9
- A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of AgeCompletedPhase 1/2GlaxoSmithKlineNCT05496231Written as Gardasil 9
- A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) VaccineActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT06207175Written as GARDASIL® 9
- Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCompletedPhase 3Shanghai Bovax Biotechnology Co., Ltd.NCT05372016Written as Active Comparator: GARDASIL ®9
- Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of AgeCompletedPhase 3Xiamen UniversityNCT04782895Written as Gardasil®9
- A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in ChinaActive, not recruitingPhase 3Beijing Health Guard Biotechnology, IncNCT05662020Written as GARDASIL® 9
- Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9Status unknownPhase 3Shanghai Zerun Biotechnology Co.,LtdNCT05580341Written as GARDASIL ®9
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting2
- The Mother-Daughter Project: Merck-4Nov 10, 2026NCT07240220
- A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)Oct 22, 2026NCT07785843
Results posted2
- HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPVOct 28, 2026NCT03284866
- HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in EswatiniOct 27, 2026NCT04982614